Here's the Deal
 

Baird's Investment Banking Group is pleased to announce the following transaction:

October 2007


Obagi Medical Products Inc.
Follow-On Offering
$144.9 Million


Robert W. Baird & Co. acted as bookrunning manager on this transaction.


Obagi Medical Products, Inc. (NASDAQ: OMPI) (“Obagi” or the “Company”) recently announced a follow-on offering of 7,245,000 shares of its common stock at $20.00 a share. The $144.9 million offering included 800,000 shares offered by the Company and 6,445,000 shares offered by selling shareholders. The Company intends to use the proceeds of this offering to pay down debt outstanding on its credit facility and for general corporate purposes.

Obagi is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. The Company develops and commercializes prescription-based, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyperpigmentation (irregular or patchy discoloration of the skin), acne and soft tissue deficits, such as fine lines and wrinkles. Their products are designed to improve the underlying health of patients’ skin, and their clinical studies have demonstrated that the use of their Obagi Nu-Derm System results in skin that looks and acts younger and healthier.

The Baird team included our dedicated Healthcare industry bankers and members of our Equity Capital Markets Group.

For additional information about this transaction, please contact:
Managing Director
312.609.4920
Managing Director
404.240.5792
Director
414.765.7079

Social Icons

Careers|Help|Site Map|Important Disclosures|Privacy Policy|Financial Information|Business Continuity
©2013 Robert W. Baird & Co. Incorporated.
Global Websites: Europe | Asia
The services featured on this Web site may not be available in all jurisdictions or to all persons/entities. For more information, please see Important Disclosures. Robert W. Baird & Co. Incorporated. Member SIPC.